---
title: "Takeda faces major AMITIZA antitrust verdict and prepares FY2025 provision"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286840681.md"
description: "Takeda Pharmaceutical Co faces a significant antitrust verdict regarding its constipation drug AMITIZA, with a Massachusetts jury awarding nearly USD 885 million in damages. The company disputes the ruling and plans to recognize a provision in its FY2025 results, although it expects no impact on core figures. Takeda may revise its FY2026 outlook based on further assessments. The current analyst rating for Takeda stock is a Buy with a price target of Yen6900.00."
datetime: "2026-05-19T01:52:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286840681.md)
  - [en](https://longbridge.com/en/news/286840681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286840681.md)
---

# Takeda faces major AMITIZA antitrust verdict and prepares FY2025 provision

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Takeda Pharmaceutical Co ( (JP:4502) ) just unveiled an announcement.

Takeda said a Massachusetts jury returned a verdict against the company in U.S. antitrust litigation over the constipation drug AMITIZA, awarding nearly USD 885 million in single damages to wholesalers, retailers and end payors, with certain portions subject to automatic trebling. The company disputes the outcome, arguing its 2014 patent settlement over AMITIZA’s generic entry was lawful and stressing that any final liability, potential provision size and impact on its financial statements will depend on post-trial proceedings and appeals.

The drugmaker plans to recognize a provision related to the case in its FY2025 consolidated results and will restate that year’s earnings and financial materials once the amount is set, although it expects no effect on FY2025 core figures. Takeda does not foresee a material hit to its FY2026 outlook beyond possible changes to adjusted free cash flow, but signaled it may revise guidance once it completes its assessment and clarifies the timing and scale of any cash payments.

The most recent analyst rating on (JP:4502) stock is a Buy with a Yen6900.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.

**More about Takeda Pharmaceutical Co**

Takeda Pharmaceutical Co. is a Japan-headquartered, R&D-driven biopharmaceutical company focused on gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. It operates globally in about 80 countries, aiming to deliver life-transforming treatments through a broad pipeline developed in partnership with external collaborators.

**Average Trading Volume:** 4,511,087

**Technical Sentiment Signal:** Buy

**Current Market Cap:** Yen8365.2B

See more insights into 4502 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31](https://longbridge.com/en/news/286837374.md)
- [Takeda Pharmaceutical (NYSE:TAK) Posts Quarterly Earnings Results, Beats Expectations By $0.36 EPS](https://longbridge.com/en/news/286621568.md)
- [Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results](https://longbridge.com/en/news/286858624.md)
- [Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict](https://longbridge.com/en/news/287084055.md)
- [Jury Hits Takeda With $885 Million Antitrust Verdict](https://longbridge.com/en/news/286951697.md)